title: Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment.
abstract: Finasteride is a well-known inhibitor of the prostatic enzyme 5 alpha-reductase type 2 which prevents conversion of testosterone into 5 alpha-dihydrotestosterone, the active intraprostatic androgen, which causes prostate involution through a combination of cell atrophy and cell death. The drug is widely used to improve symptoms of benign prostatic hyperplasia in man. Clusterin, a glycoprotein which is generally up-regulated under conditions inducing cell atrophy or organ involution, is produced at a high level in the regressing rat ventral prostate following androgen ablation. According to several authors, clusterin does not respond to finasteride treatment, suggesting a different action of testosterone and 5 alpha-dihydrotestosterone. We show here that, under our conditions, finasteride was capable of inducing production of both clusterin mRNA and protein in the rat ventral prostate. In fact, by using different and converging techniques, such as Northern hybridization, in situ hybridization histochemistry and immunohistochemistry, we were able to show a strong induction of the clusterin gene in the epithelial cell population of the gland. The response to finasteride, which was similar to that seen with castration, occurred with a delay of a few days. In situ and immunohistochemistry experiments indicated that both orchidectomy and finasteride administration resulted in increased transition of the epithelial cells from the columnar to the cuboidal (atrophic) shape, and this was accompanied by an increased intensity of the signal for clusterin. Thus, it appears that induction of clusterin is part of the molecular process leading to prostate involution caused by either orchidectomy or finasteride administration.
authors.affiliation: Dipartimento di Scienze Biomediche, Università di Modena e Reggio Emilia, Via G. Campi 287, 41100 Modena, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Astancolle
authors.forename: G
authors.initials: G
authors.lastname: Guidetti
authors.forename: C
authors.initials: C
authors.lastname: Pinna
authors.forename: A
authors.initials: A
authors.lastname: Corti
authors.forename: S
authors.initials: S
authors.lastname: Bettuzzi
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000818:Animals; D015152:Blotting, Northern; D051152:Clusterin; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018120:Finasteride / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D008297:Male; D018832:Molecular Chaperones; D009919:Orchiectomy; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D058891:5-alpha Reductase Inhibitors; D051152:Clusterin; D004791:Enzyme Inhibitors; D006023:Glycoproteins; D018832:Molecular Chaperones; D012333:RNA, Messenger; D018120:Finasteride